GNI is a Tokyo-based company founded in 2001.
GNI Group Ltd. is a company operating in the pharmaceutical industry, based in Tokyo, Japan. Having been founded in November 2001, the company is currently active and listed on the Tokyo Stock Exchange with the stock symbol 2160. GNI is a B2B organization with a workforce of 629 employees.
Ying Luo serves as the CEO of GNI Group Ltd.. The company has a significant presence in other countries, including China and the United States. In addition to its headquarters in Tokyo, GNI maintains offices in Berkeley, California, Shanghai, San Diego, Tianjin, and Beijing.
GNI has been assigned one patent. They are also linked to the University of Tokyo Edge Capital as an investor in the company.